The signaling duo CXCL12 and CXCR4: chemokine fuel for breast cancer tumorigenesis

KA Zielińska, VL Katanaev - Cancers, 2020 - mdpi.com
Simple Summary Breast cancer remains the most common malignancy in women. In this
review, we explore the role of the CXCL12/CXCR4 pathway in breast cancer. We show that …

Molecular insights into therapeutic potential of autophagy modulation by natural products for cancer stem cells

MA Rahman, SK Saha, MS Rahman… - Frontiers in cell and …, 2020 - frontiersin.org
Autophagy, a cellular self-digestion process that is activated in response to stress, has a
functional role in tumor formation and progression. Cancer stem cells (CSCs) accounting for …

Explaining decisions of graph convolutional neural networks: patient-specific molecular subnetworks responsible for metastasis prediction in breast cancer

H Chereda, A Bleckmann, K Menck, J Perera-Bel… - Genome medicine, 2021 - Springer
Background Contemporary deep learning approaches show cutting-edge performance in a
variety of complex prediction tasks. Nonetheless, the application of deep learning in …

YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer

D Jiang, T Qiu, J Peng, S Li, Tala, W Ren… - Cell Death & …, 2022 - nature.com
Y-box binding protein 1 (YB-1) is a well-known oncogene highly expressed in various
cancers, including basal-like breast cancer (BLBC). Beyond its role as a transcription factor …

Proteomics-Based identification of dysregulated proteins and biomarker discovery in invasive ductal carcinoma, the most common breast cancer subtype

AN Neagu, D Whitham, L Seymour, N Haaker, I Pelkey… - Proteomes, 2023 - mdpi.com
Invasive ductal carcinoma (IDC) is the most common histological subtype of malignant
breast cancer (BC), and accounts for 70–80% of all invasive BCs. IDC demonstrates great …

[HTML][HTML] TFAP2A induced KRT16 as an oncogene in lung adenocarcinoma via EMT

L Yuanhua, Q Pudong, Z Wei, W Yuan… - … journal of biological …, 2019 - ncbi.nlm.nih.gov
Objectives: keratin 16 (KRT16) is a type I cytokeratin that overexpressed in many kinds of
cancers, but unlike other keratins, KRT16 was poorly studied, so the aim of current study …

PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models

KC Park, JM Kim, SY Kim, SM Kim, JH Lim, MK Kim… - BMC medicine, 2023 - Springer
Background Cancer cells have developed molecular strategies to cope with evolutionary
stressors in the dynamic tumor microenvironment. Peroxisome proliferator-activated receptor …

Molecular data representation based on gene embeddings for cancer drug response prediction

S Park, H Lee - Scientific Reports, 2023 - nature.com
Cancer drug response prediction is a crucial task in precision medicine, but existing models
have limitations in effectively representing molecular profiles of cancer cells. Specifically …

“In the light of evolution:” keratins as exceptional tumor biomarkers

I Takan, G Karakülah, A Louka, A Pavlopoulou - PeerJ, 2023 - peerj.com
Keratins (KRTs) are the intermediate filament-forming proteins of epithelial cells, classified,
according to their physicochemical properties, into “soft” and “hard” keratins. They have a …

[HTML][HTML] Epithelial-mesenchymal plasticity—engaging stemness in an interplay of phenotypes

VL Chin, CL Lim - Stem Cell Investigation, 2019 - ncbi.nlm.nih.gov
Cancer is a genetic disease which results in a functional imbalance between tumour-
repressive and oncogenic signals. The WHO highlights the burden of this indomitable …